Four phase III trials have been completed that evaluated the combination of VEGF/VEGFR-targeted therapy and immune checkpoint inhibitors (biologic molecules) vs. targeted therapy alone, namely with sunitinib, and results have been collected in untreated sarcomatoid and non-sarcomatoid ccRCC [1] (Table 2). The gene discussed is VEGFA; the disease is nonpapillary renal cell carcinoma.